B
티디에스팜
464280KOSDAQ의약품 제조업59.5 / 100
Reference Date: 2026-07-24
Financial Score30.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Declined 7.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
TDS Pharm specializes in the development and manufacturing of transdermal drug delivery systems (TDDS), holding a leading position in the Korean market with key products like Cataplasma and Plaster. The company aims to grow into a global pharmaceutical firm by expanding its portfolio to include patches targeting dementia, asthma, nicotine addiction, and other therapeutic areas.
Number of Employees
111people
Average Salary
32.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
7.06Industry Average 11.236.5Point
Lower than industry avg (good)
PBR
0.71Industry Average 0.814.0Point
In line with industry avg
ROE
10.52Industry Average 4.017.0Point
2.6x industry avg (excellent)
Debt Ratio
0.38Industry Average 12.438.0Point
Half of industry avg (excellent)
Trend 2024~20254.5 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲0.4% (1-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲0.9% (1-year basis)
ROE Trend
2.5 / 4
Avg ROE 11.3% (declining, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 5,460Won52-week high 11,43052-week low 5,420
1-month return1.0Point
1m -7.61% (falling)
Volume trend5.0Point
Volume flat
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral임시주주총회결과2026-07-15
- Neutral주주총회소집공고2026-06-30
- Neutral[기재정정]사업보고서 (2025.12)2026-06-29
- Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-06-29
- Neutral[기재정정]사업보고서 (2025.12)2026-06-29